Non‐viral vector‐mediated uptake, distribution, and stability of chimeraplasts in human airway epithelial cells
- 16 April 2002
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 4 (3) , 308-322
Abstract
Background: Chimeraplasty is a novel methodology that uses chimeric RNA/DNA oligonucleotides (chimeraplasts) to stimulate genomic DNA repair. Efficient uptake and nuclear localization of intact chimeraplasts are key parameters to achieve optimal correction of mutation defects into specific cell types.Methods: A 5′‐end FITC‐labeled 68‐mer RNA/DNA oligonucleotide was complexed with the polycation polyethylenimine (PEI) and the cationic lipids Cytofectin and GenePorter. Flow cytometry was employed to evaluate chimeraplast uptake under different conditions. Intracellular chimeraplast distribution and co‐localization with endocytosis markers were assessed by confocal microscopy. Relative quantification of chimeraplast metabolism was performed by denaturing PAGE and GeneScan™ analysis.Results: In airway epithelial cells, optimized chimeraplast uptake reached near 100% efficiency with the carriers tested. However, chimeraplast nuclear localization could only be achieved using PEI or Cytofectin. Chimeraplast/GenePorter lipoplexes were retained in the cytoplasm. PEI polyplexes and Cytofectin lipoplexes displayed different uptake rates and internalization mechanisms. Chimeraplast/PEI polyplexes were internalized at least partially by fluid‐phase endocytosis. In contrast, phagocytosis may have contributed to the internalization process of large‐sized chimeraplast/Cytofectin lipoplexes. Moreover, significant chimeraplast degradation was detected 24 h after transfection with both PEI polyplexes and Cytofectin lipoplexes, although the latter seemed to confer a higher degree of protection against nuclease degradation.Conclusion: Both Cytofectin and PEI are efficient for chimeraplast nuclear uptake into airway epithelial cells. However, despite the distinct structures and trafficking pathways of the corresponding complexes, none of them could prevent nuclease‐mediated metabolism of the chimeric oligonucleotides. These findings should be taken into account for future investigations of chimeraplast‐mediated gene repair in airway epithelial cells. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
Funding Information
- Fundació la Marató de TV3 (98/1610)
- Associació Catalana de Fibrosi Quística
This publication has 59 references indexed in Scilit:
- The potential of nucleic acid repair in functional genomicsNature Biotechnology, 2001
- In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotideNature Biotechnology, 2000
- Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotidesProceedings of the National Academy of Sciences, 2000
- Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotideNature Biotechnology, 2000
- Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler–Najjar syndrome type I with a chimeric oligonucleotideProceedings of the National Academy of Sciences, 1999
- Therapeutic repair of mutated nucleic acid sequencesNature Biotechnology, 1998
- Therapeutic gene targetingGene Therapy, 1998
- Correction of the Mutation Responsible for Sickle Cell Anemia by an RNA-DNA OligonucleotideScience, 1996
- Transfer of Genes to Humans: Early Lessons and Obstacles to SuccessScience, 1995
- The Basic Science of Gene TherapyScience, 1993